Ascendis Pharma A/S reports results for the quarter ended in March - Earnings Summary

Ascendis Pharma A/S

11/05/2022 22:58

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €2.21​​ per share for the quarter ended in March. The mean
expectation of twelve analysts for the quarter was for a loss of
€2.00 per share.
    * Revenue rose 815.3% to €6.83 million from a year ago; 
analysts
expected €4.67 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€2.21​.
    * The mean earnings estimate of analysts had risen by
about 5% in
the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Ascendis Pharma A/S shares had fallen by 29.6% this
quarter and
lost 38.6% so far this year.
    * The company reported a quarterly loss of €125.5 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $191.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 11 at 09:58 p.m.  ​All
figures in euros unless otherwise stated